tbuckley/cabot-search huggingface dataset:
Diversity and epitope spreading of anti‐<scp>RNA</scp> polymerase <scp>III</scp> antibodies in systemic sclerosis: a potential biomarker for skin and lung involvement
Authors: Hirohito Kotani, Kazuki M. Matsuda, Kei Yamaguchi, Chihiro Ono, Emi Kogo, Koji Ogawa, Yuki Kobayashi, Teruyoshi Hisamoto, Ruriko Kawanabe, Ai Kuzumi, Takemichi Fukasawa, Asako Yoshizaki‐Ogawa, Naoki Goshima, Shinichi Sato, Ayumi Yoshizaki
Journal: Arthritis & Rheumatology (2024)

Objective Epitope spreading (ES), involving autoantibodies, plays a crucial role in the development and persistence of autoimmune reactions in various autoimmune diseases. This study aimed to investigate the relationship between ES of anti–RNA polymerase III (RNAP III) antibodies (ARAs) and the clinical manifestations of systemic sclerosis (SSc). Methods We investigated whether intermolecular ES occurs in the subunits of the RNAP III complex and whether intramolecular ES targets the major antigen, RNA polymerase III subunit A (RPC1), in patients with SSc. To achieve this, we synthesized 17 full‐length subunit proteins of the RNAP III complex and 5 truncated forms of RPC1 in vitro using a wheat germ cell‐free translation system. Subsequently, we prepared antigen‐binding plates and measured autoantibodies in the serum of patients with SSc. Results Autoantibodies against different RNAP III complex subunits were found in patients who were ARA‐positive with SSc. The intermolecular ES indicators significantly correlated with the modified Rodnan skin thickness score (mRSS) and surfactant protein‐D, a biomarker of interstitial lung disease. However, the extent of disease on high‐resolution computed tomography or pulmonary function tests did not show any significant correlation. Intramolecular ES indicator against RPC1 were significantly correlated with mRSS and renal crisis. Furthermore, longitudinal assessment of ES in RNAP III complex subunits correlated with mRSS and exhibited potential as a disease activity biomarker. Conclusion Our findings indicate a correlation between ES levels and the severity of skin sclerosis or the risk of other complications in SSc. This study suggests that measuring ES in SSc serves as a novel biomarker for disease activity. image
Electrospun Poly‐<scp>l</scp>‐Lactic Acid Membranes Promote M2 Macrophage Polarization by Regulating the PCK2/AMPK/mTOR Signaling Pathway (Adv. Healthcare Mater. 22/2024)
Authors: Daiyuan Tang, Bing Han, Chengkai He, Yunrong Xu, Zhui Liu, Weizhou Wang, Zaitian Huang, Zhenping Xiao, Fei He
Journal: Advanced Healthcare Materials (2024)
Posttransplant complications: molecular mechanisms and therapeutic interventions
Authors: Xiaoyou Liu, Junyi Shen, Hongyan Yan, Jianmin Hu, Guorong Liao, Ding Liu, Song Zhou, Jie Zhang, Jun Liao, Zefeng Guo, Yuzhu Li, Siqiang Yang, Shichao Li, Hua Chen, Ying Guo, Min Li, Lipei Fan, Liuyang Li, Peng Luo, Ming Zhao, Yongguang Liu
Journal: MedComm (2024)

Posttransplantation complications pose a major challenge to the long-term survival and quality of life of organ transplant recipients. These complications encompass immune-mediated complications, infectious complications, metabolic complications, and malignancies, with each type influenced by various risk factors and pathological mechanisms. The molecular mechanisms underlying posttransplantation complications involve a complex interplay of immunological, metabolic, and oncogenic processes, including innate and adaptive immune activation, immunosuppressant side effects, and viral reactivation. Here, we provide a comprehensive overview of the clinical features, risk factors, and molecular mechanisms of major posttransplantation complications. We systematically summarize the current understanding of the immunological basis of allograft rejection and graft-versus-host disease, the metabolic dysregulation associated with immunosuppressive agents, and the role of oncogenic viruses in posttransplantation malignancies. Furthermore, we discuss potential prevention and intervention strategies based on these mechanistic insights, highlighting the importance of optimizing immunosuppressive regimens, enhancing infection prophylaxis, and implementing targeted therapies. We also emphasize the need for future research to develop individualized complication control strategies under the guidance of precision medicine, ultimately improving the prognosis and quality of life of transplant recipients.
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation
Authors: Pengyun Li, Xiaotong Hu, Zhiya Fan, Shiyang Sun, Qijie Ran, Ting Wei, Pengli Wei, Qiyu Jiang, Jian Yan, Ning Yang, Changkai Jia, Tingting Yang, Yaqiu Mao, Xu Cai, Tingting Xu, Zhiyuan Zhao, Xiaohong Qian, Weijie Qin, Xiaomei Zhuang, Feng Fan, Junhai Xiao, Zhibing Zheng, Song Li
Journal: Journal of Hematology & Oncology (2024)

Targeted protein degradation of neosubstrates plays a crucial role in hematological cancer treatment involving immunomodulatory imide drugs (IMiDs) therapy. Nevertheless, the persistence of inevitable drug resistance and hematological toxicities represents a significant obstacle to their clinical effectiveness. Phenotypic profiling of a small molecule compounds library in multiple hematological cancer cell lines was conducted to screen for hit degraders. Molecular dynamic-based rational design and cell-based functional assays were conducted to develop more potent degraders. Multiple myeloma (MM) tumor xenograft models were employed to investigate the antitumor efficacy of the degraders as single or combined agents with standard of care agents. Unbiased proteomics was employed to identify multiple therapeutically relevant neosubstrates targeted by the degraders. MM patient-derived cell lines (PDCs) and a panel of solid cancer cell lines were utilized to investigate the effects of candidate degrader on different stage of MM cells and solid malignancies. Unbiased proteomics of IMiDs-resistant MM cells, cell-based functional assays and RT-PCR analysis of clinical MM specimens were utilized to explore the role of BRD9 associated with IMiDs resistance and MM progression. We identified a novel cereblon (CRBN)-dependent lead degrader with phthalazinone scaffold, MGD-4, which induced the degradation of Ikaros proteins. We further developed a novel potent candidate, MGD-28, significantly inhibited the growth of hematological cancer cells and induced the degradation of IKZF1/2/3 and CK1α with nanomolar potency via a Cullin-CRBN dependent pathway. Oral administration of MGD-4 and MGD-28 effectively inhibited MM tumor growth and exhibited significant synergistic effects with standard of care agents. MGD-28 exhibited preferentially profound cytotoxicity towards MM PDCs at different disease stages and broad antiproliferative activity in multiple solid malignancies. BRD9 modulated IMiDs resistance, and the expression of BRD9 was significant positively correlated with IKZF1/2/3 and CK1α in MM specimens at different stages. We also observed pronounced synergetic efficacy between the BRD9 inhibitor and MGD-28 for MM treatment. Our findings present a strategy for the multi-targeted degradation of Ikaros proteins and CK1α against hematological cancers, which may be expanded to additional targets and indications. This strategy may enhance efficacy treatment against multiple hematological cancers and solid tumors.
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial
Authors: Jing Lu, Huiying Qiu, Ying Wang, Xin Zhou, Haiping Dai, Xuzhang Lu, Xiaofei Yang, Bin Gu, Ming Hong, Miao Miao, Ruinan Lu, Jun Wang, Qian Wu, Mengxing Xue, Yun Wang, Ailing Deng, Yaoyao Shen, Yin Liu, Xueqing Dou, Yutian Lei, Depei Wu, Yu Zhu, Suning Chen
Journal: Journal of Hematology & Oncology (2024)

Blinatumomab has emerged as a promising component of first-line therapy for acute B-cell precursor lymphoblastic leukemia (BCP-ALL), bolstering treatment efficacy. To mitigate CD19 selection pressure and reduce the incidence of blinatumomab-associated toxicities, pre-treatment chemotherapy is recommended before administering blinatumomab. From September 2022 to December 2023, we conducted a single-arm, multicenter, phase 2 trial (NCT05557110) in newly diagnosed Philadelphia chromosome-negative BCP-ALL (Ph-negative BCP-ALL) patients. Participants received induction treatment with reduced-dose chemotherapy (RDC), comprising idarubicin, vindesine, and dexamethasone over 7 days, followed by 2 weeks of blinatumomab. Those failing to achieve composite complete remission (CRc) received an additional 2 weeks of blinatumomab. The primary endpoint was the CRc rate post initial induction treatment. Of the 35 enrolled patients, 33 (94%) achieved CRc after 2 weeks of blinatumomab, with 30 (86%) achieving measurable residual disease (MRD) negativity. Two patients extended blinatumomab to 4 weeks. With either 2 or 4 weeks of blinatumomab treatment, all patients achieved CR (35/35) and 89% (31/35) were MRD negativity. The median time to CR was 22 days. Immune effector cell-associated neurotoxicity syndrome was limited (14%, all grade 1). Non-hematological adverse events of grade 3 or higher included pneumonia (17%), sepsis (6%), and cytokine release syndrome (9%). With a median follow-up of 11.5 months, estimated 1-year overall survival and 1-year progression-free survival rates were 97.1% and 82.2%, respectively. These findings affirm that RDC followed by blinatumomab is an effective and well-tolerated induction regimen for newly diagnosed Ph-negative BCP-ALL, supporting a shift towards less intensive and more targeted therapeutic approaches. Trial registration: https://www.clinicaltrials.Gov . Identifier NCT05557110.
Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells
Authors: Yaqing Qie, Martha E. Gadd, Qing Shao, Tommy To, Andrew Liu, Shuhua Li, Rocio Rivera‐Valentin, Farah Yassine, Hemant S. Murthy, Roxana Dronca, Mohamed A. Kharfan‐Dabaja, Hong Qin, Yan Luo
Journal: MedComm (2024)

The challenge of disease relapsed/refractory (R/R) remains a therapeutic hurdle in chimeric antigen receptor (CAR) T-cell therapy, especially for hematological diseases, with chronic lymphocytic leukemia (CLL) being particularly resistant to CD19 CAR T cells. Currently, there is no approved CAR T-cell therapy for CLL patients. In this study, we aimed to address this unmet medical need by choosing the B-cell activating factor receptor (BAFF-R) as a promising target for CAR design against CLL. BAFF-R is essential for B-cell survival and is consistently expressed on CLL tumors. Our research discovered that BAFF-R CAR T-cell therapy exerted the cytotoxic effects on both CLL cell lines and primary B cells derived from CLL patients. In addition, the CAR T cells exhibited cytotoxicity against CD19-knockout CLL cells that are resistant to CD19 CAR T therapy. Furthermore, we were able to generate BAFF-R CAR T cells from small blood samples collected from CLL patients and then demonstrated the cytotoxic effects of these patient-derived CAR T cells against autologous tumor cells. Given these promising results, BAFF-R CAR T-cell therapy has the potential to meet the long-standing need for an effective treatment on CLL patients.
Reconfigurable Hanging Drop Microarray Platform for On‐Demand Preparation and Analysis of Spheroid Array (Adv. Healthcare Mater. 22/2024)
Authors: Hwisoo Kim, Bumsoo Kim, Soo Jee Kim, Yejin Choi, Irene Hae‐Rim Kim, Jieun Han, Young‐Gyun Park, Yong‐Mahn Han, Je‐Kyun Park
Journal: Advanced Healthcare Materials (2024)
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction
Authors: C. Michael Gibson, Gerald Chi, Danielle Duffy, M. Cecilia Bahit, Harvey White, Serge Korjian, John H. Alexander, A. Michael Lincoff, Gaya Anschuetz, Ihab G. Girgis, Jose C. Nicolau, Renato D. Lopes, Jan H. Cornel, Kevin R. Bainey, Peter Libby, Frank M. Sacks, Paul M Ridker, Shaun G. Goodman, Kenneth W. Mahaffey, Stephen J. Nicholls, Stuart J. Pocock, Roxana Mehran, Robert A. Harrington
Journal: Journal of the American College of Cardiology (2024)
Fatal meningoencephalitis associated with Ebola virus persistence in two survivors of Ebola virus disease in the Democratic Republic of the Congo: a case report study
Authors: Daniel Mukadi-Bamuleka, François Edidi-Atani, Maria E Morales-Betoulle, Anaïs Legand, Antoine Nkuba-Ndaye, Junior Bulabula-Penge, Placide Mbala-Kingebeni, Ian Crozier, Fabrice Mambu-Mbika, Shannon Whitmer, Olivier Tshiani Mbaya, Lisa E Hensley, Richard Kitenge-Omasumbu, Richard Davey, Sabue Mulangu, Peter N Fonjungo, Michael R Wiley, John D Klena, Martine Peeters, Eric Delaporte, Johan van Griensven, Kevin K Ariën, Catherine Pratt, Joel M Montgomery, Pierre Formenty, Jean-Jacques Muyembe-Tamfum, Steve Ahuka-Mundeke, Anja De Weggheleire, Gnakub N Soke, Raymond Pallawo, Gouressy Ibrahima, Victor Epaso Gelege, John Kombe-Ngwama, Grace Kahambwe-Ekoko, Mathias Mossoko Gbe, Pierre-Céleste Adikey Limne, Etienne Yuma-Kibondo, Eddy Kinganda-Lusamaki, Adrienne Amuri Aziza, Yannick Tutu Tshia N'kasar, Elias Mumbere Kalemekwa, Divine Kitsa-Mutsumbirwa, Noella Mulopo-Mukanya, Fyfy Mbelu-Matulu, Marie-Anne Kavira-Muhindo, Jacques Kwizera Sendegeya, Hugo Kavunga-Membo
Journal: The Lancet Microbe (2024)

During the 2018-20 Ebola virus disease outbreak in the Democratic Republic of the Congo, thousands of patients received unprecedented vaccination, monoclonal antibody (mAb) therapy, or both, leading to a large number of survivors. We aimed to report the clinical, virological, viral genomic, and immunological features of two previously vaccinated and mAb-treated survivors of Ebola virus disease in the Democratic Republic of the Congo who developed second episodes of disease months after initial discharge, ultimately complicated by fatal meningoencephalitis associated with viral persistence.
Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial
Authors: Chao Gao, Xingqiang He, Fan Ouyang, Zhihui Zhang, Guidong Shen, Mingxing Wu, Ping Yang, Likun Ma, Feng Yang, Zheng Ji, Hua Wang, Yanqing Wu, Zhenfei Fang, Hong Jiang, Shangyu Wen, Yi Liu, Fei Li, Jingyu Zhou, Bin Zhu, Yunpeng Liu, Ruining Zhang, Tingting Zhang, Ping Wang, Jianzheng Liu, Zhiwei Jiang, Jielai Xia, Robert-Jan van Geuns, Davide Capodanno, Scot Garg, Yoshinobu Onuma, Duolao Wang, Patrick W Serruys, Ling Tao
Journal: The Lancet (2024)
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Authors: Gerald F Watts, Robert S Rosenson, Robert A Hegele, Ira J Goldberg, Antonio Gallo, Ann Mertens, Alexis Baass, Rong Zhou, Ma'an Muhsin, Jennifer Hellawell, Nicholas J Leeper, Daniel Gaudet
Journal: New England Journal of Medicine (2024)

BackgroundPersistent chylomicronemia is a genetic recessive disorder that is classically caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes. The disorder is associated with the risk of recurrent acute pancreatitis. Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III and circulating triglycerides.MethodsIn a phase 3 trial, we randomly assigned 75 patients with persistent chylomicronemia (with or without a genetic diagnosis) to receive subcutaneous plozasiran (25 mg or 50 mg) or placebo every 3 months for 12 months. The primary end point was the median percent change from baseline in the fasting triglyceride level at 10 months. Key secondary end points were the percent change in the fasting triglyceride level from baseline to the mean of values at 10 months and 12 months, changes in the fasting apolipoprotein C-III level from baseline to 10 months and 12 months, and the incidence of acute pancreatitis.ResultsAt baseline, the median triglyceride level was 2044 mg per deciliter. At 10 months, the median change from baseline in the fasting triglyceride level (the primary end point) was −80% in the 25-mg plozasiran group, −78% in the 50-mg plozasiran group, and −17% in the placebo group (P<0.001). The key secondary end points showed better results in the plozasiran groups than in the placebo group, including the incidence of acute pancreatitis (odds ratio, 0.17; 95% confidence interval, 0.03 to 0.94; P=0.03). The risk of adverse events was similar across groups; the most common adverse events were abdominal pain, nasopharyngitis, headache, and nausea. Severe and serious adverse events were less common with plozasiran than with placebo. Hyperglycemia with plozasiran occurred in some patients with prediabetes or diabetes at baseline.ConclusionsPatients with persistent chylomicronemia who received plozasiran had significantly lower triglyceride levels and a lower incidence of pancreatitis than those who received placebo. (Funded by Arrowhead Pharmaceuticals; PALISADE ClinicalTrials.gov number, NCT05089084.)
Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea
Authors: Sung-Jin Hong, Seung-Jun Lee, Sang-Hyup Lee, Jong-Young Lee, Deok-Kyu Cho, Jin Won Kim, Sang Min Kim, Seung-Ho Hur, Jung Ho Heo, Ji-Yong Jang, Jin Sin Koh, Hoyoun Won, Jun-Won Lee, Soon Jun Hong, Dong-Kie Kim, Jeong Cheon Choe, Jin Bae Lee, Soo-Joong Kim, Tae-Hyun Yang, Jung-Hee Lee, Young Joon Hong, Jong-Hwa Ahn, Yong-Joon Lee, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Byeong-Keuk Kim
Journal: The Lancet (2024)
Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation
Authors: Paul M. Haller, Petr Jarolim, Michael G. Palazzolo, Andrea Bellavia, Elliott M. Antman, John Eikelboom, Christopher B. Granger, Josephine Harrington, Jeff S. Healey, Ziad Hijazi, Manesh R. Patel, Siddharth M. Patel, Christian T. Ruff, Lars Wallentin, Eugene Braunwald, Robert P. Giugliano, David A. Morrow
Journal: Journal of the American College of Cardiology (2024)
Prolonged, staged, and self-regulated methotrexate release coupled with ROS scavenging in an injectable hydrogel for rheumatoid arthritis therapy
Authors: Mingsheng Xu, Tingting Fu, Chenhui Zhang, Zhen An, Jincong Yan, Zhongzhong Lu, Hanfei Wu, Jihuan Liu, Lei Qiu, Lei Shi, Jun Lin, Yi Cao, Renjun Pei
Journal: Journal of Controlled Release (2024)
In situ formed reactive oxygen species-responsive dipyridamole prodrug hydrogel: Spatiotemporal drug delivery for chemoimmunotherapy
Authors: Bing Xiao, Xueying Shi, Xiaodan Xu, Jiwei Liu, Yixuan Pan, Hongxia Xu, Wenjing Sun, Nigel K H Slater, Hirak K Patra, Jianqing Gao, Youqing Shen, Jianbin Tang
Journal: Journal of Controlled Release (2024)
Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates
Authors: T Tedeschini, B Campara, A Grigoletto, I Zanotto, L Cannella, D Gabbia, Y Matsuno, A Suzuki, H Yoshioka, A Armirotti, S De Martin, G Pasut
Journal: Journal of Controlled Release (2024)

In this work, we conceived and developed antibody-drug conjugates (ADCs) that could efficiently release the drug after enzymatic cleavage of the linker moiety by tumoral proteases. The antibody-drug linkers we used are the result of a rational optimization of a previously reported PEGylated linker, PUREBRIGHT® MA-P12-PS, which showed excellent drug loading capacities but lacked an inbuilt drug discharge mechanism, thus limiting the potency of the resulting ADCs. To address this limitation, we chose to incorporate a protease-sensitive trigger into the linker to favor the release of a "PEGless" drug inside the tumor cells and, therefore, obtain potent ADCs. Currently, most marketed ADCs are based on the Val-Cit dipeptide followed by a self-immolative spacer for releasing the drug in its unmodified form. Here, we selected two untraditional peptide sequences, a Phe-Gly dipeptide and a Val-Ala-Gly tripeptide and placed one or the other in between the drug on one side (N-terminus) and the rest of the linker, including the PEG moiety, on the other side (C-terminus), without a self-immolative group. We found that both linkers responded to cathepsin B, a reference lysosomal enzyme, and liberated a PEG-free drug catabolite, as desired. We then used the two linkers to generate ADCs based on trastuzumab (a HER2-targeting antibody) and DM1 (a microtubule-targeted cytotoxic agent) with an average drug-to-antibody ratio (DAR) of 4 or 8. The ADCs showed restored cytotoxicity in vitro, which was proportional to the DM1 loading and generally higher for the ADCs bearing Val-Ala-Gly in their structure. In an ovarian cancer model in mice, the DAR 8 ADC based on Val-Ala-Gly behaved better than Kadcyla® (an approved ADC of DAR 3.5 used as control throughout this study), leading to a higher tumor volume reduction and more prolonged median survival. Taken together, our results depict a successful linker optimization process and encourage the application of the Val-Ala-Gly tripeptide as an alternative to other existing protease-sensitive triggers for ADCs.
Reprogramming monocytes into M2 macrophages as living drug depots to enhance treatment of myocardial ischemia-reperfusion injury
Authors: Yan Liu, Meiling Zhou, Maochang Xu, Xueqin Wang, Yingying Zhang, Yiping Deng, Zongquan Zhang, Jun Jiang, Xiangyu Zhou, Chunhong Li
Journal: Journal of Controlled Release (2024)
Chondroitin sulfate-based microneedles for transdermal delivery of stem cell-derived extracellular vesicles to treat rheumatoid arthritis
Authors: Van Dat Bui, Jueun Jeon, Van Hieu Duong, Sol Shin, Jungmi Lee, Farrokhroo Ghahari, Chan Ho Kim, Yu Jin Jo, Won-Kyo Jung, Wooram Um, Jae Hyung Park
Journal: Journal of Controlled Release (2024)
Pulmonary hypertension associated with lung diseases
Authors: Oksana A Shlobin, Yochai Adir, Joan A Barbera, Vincent Cottin, Sergio Harari, Etienne-Marie Jutant, Joanna Pepke-Zaba, Hossein-Ardeschir Ghofrani, Richard Channick
Journal: European Respiratory Journal (2024)

Pulmonary hypertension (PH) associated with chronic lung disease (CLD) is both common and underrecognised. The presence of PH in the setting of lung disease has been consistently shown to be associated with worse outcomes. Recent epidemiological studies have advanced understanding of the heterogeneity of this patient population and shown that defining both the specific type of CLD as well as the severity of PH ( i.e. deeper phenotyping) is necessary to inform natural history and prognosis. A systematic diagnostic approach to screening and confirmation of suspected PH in CLD is recommended. Numerous uncontrolled studies and one phase 3 randomised, controlled trial have suggested a benefit in treating PH in some patients with CLD, specifically those with fibrotic interstitial lung disease (ILD). However, other studies in diseases such as COPD-PH showed adverse outcomes with some therapies. Given the expanding list of approved pharmacological treatments for pulmonary arterial hypertension, developing a treatment algorithm for specific phenotypes of CLD-PH is required. This article will summarise existing data in COPD, ILD and other chronic lung diseases, and provide recommendations for classification of CLD-PH and approach to the diagnosis and management of these challenging patients.
Mitochondria transfer-based therapies reduce the morbidity and mortality of Leigh syndrome
Authors: Ritsuko Nakai, Stella Varnum, Rachael L. Field, Henyun Shi, Rocky Giwa, Wentong Jia, Samantha J. Krysa, Eva F. Cohen, Nicholas Borcherding, Russell P. Saneto, Rick C. Tsai, Masashi Suganuma, Hisashi Ohta, Takafumi Yokota, Jonathan R. Brestoff
Journal: Nature Metabolism (2024)
Viable Vitreous Grafts of Whole Porcine Menisci for Transplant in the Knee and Temporomandibular Joints (Adv. Healthcare Mater. 22/2024)
Authors: Shangping Wang, Dustin Mueller, Peng Chen, Ge Pan, Marshall Wilson, Shuchun Sun, Zhenzhen Chen, Thomas Lee, Brooke Damon, R. Glenn Hepfer, Cherice Hill, Michael J. Kern, William M. Pullen, Yongren Wu, Kelvin G. M. Brockbank, Hai Yao
Journal: Advanced Healthcare Materials (2024)